The present invention provides a pharmaceutical formulation comprising: an early release portion comprising as a pharmaceutical active ingredient a statin-based hypolipidic agent, an isomer thereof, or a pharmaceutically acceptable salt thereof； and a slow release portion comprising as a pharmaceutical active ingredient a dihydropyridine-based calcium channel blocking agent, an isomer thereof, or a pharmaceutically acceptable salt thereof. When compared with a single formulation of each of the drugs or a simple combination formulation of the drugs, the pharmaceutical formulation according to the present invention comprising an early release portion comprising a statin-based hypolipidic agent and a slow release portion comprising a dihydropyridine-based calcium channel blocking agent is pharmaceutically, scientifically, and economically very useful in preventing or treating cardiovascular disease, pulmonary heart disease, pulmonary disease, or kidney disease of patients who have a metabolic syndrome, insulin resistance, diabetes, or prediabetes. The formulation of the present invention is effective in preventing antagonistic and side effects between the drugs by making the dissolution rate of the statin-based hypolipidic agent different from that of the dihydropyridine-based calcium channel blocking agent, and in facilitating patient compliance in taking the drugs by administering the two different drugs simultaneously.본 발명은 활성성분으로 아토르바스타틴(Atorvastatin), 그의 이성질체 또는 그의 약학적으로 허용하는 염을 포함하는 선방출성 구획 및 약리학적 활성성분으로 암로디핀(Amlodipine), 그의 이성질체 또는 그의 약학적으로 허용하는 염을 표함하는 지연방출성 구획을 포함하는 약제학적 제제를 제공한다. 본 발명의 제제는 아토르바스타틴과 암로디핀의 용출속도를 달리 구성하여 약물 상호간의 길항 작용 및 부작용을 방지하고, 2종의 약물을 단회 투여함으로써 환자의 복용을 용이하게 하는 효과를 나타낸다.
